The first study was presented as an Eposter display titled, “1666TiP – Phase II study of berzosertib (M6620) + topotecan in patients with relapsed platinum-resistant SCLC: DDRiver SCLC 250” on Sept. 16. To read the abstract, click here.
The second study was presented as a mini oral session titled, “LBA61 – Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study” on Sept. 18. To read the abstract, click here.
Founded in 1979, CHCWM has grown to become the largest physician-owned oncology and hematology practice in Michigan. We deliver advanced care in a personal way, and our expertise and caring approach make us dedicated to the help, healing and hope for cancer patients and their families. Thanks to the hard work of our growing staff, CHCWM has been named one of the Nation’s Best and Brightest Companies to Work For®. To learn more about CHCWM, visit chcwm.com.
Becky Downing, Social Media & Marketing Specialist